KZIA

Kazia Therapeutics Limited American Depositary Shares

$12.78 +0.87%

Recent alerts on KZIA

All signals →

SEC filing KZIA Appoints James Levine CFO, 20+ Yrs Biotech Finance Experience, Former Cardiff CFO

SEC filing KZIA Expands Phase 1b Trial of Paxalisib in Advanced Breast Cancer to 36 Patients, Seeks Broader Clinical and Translational Dataset

News Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

News Nasdaq Surges 1%; JPMorgan Posts Upbeat Earnings - Benzinga

News S&P 500 Rises Over 1%; Citigroup Reports Upbeat Q2 Results - Benzinga

News Crude Oil Gains Over 1%; Virpax Pharmaceuticals Shares Spike Higher - Benzinga

News Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga

News Nasdaq Gains 1%; LegalZoom Shares Slide - Benzinga

News Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Benzinga

SEC filing KZIA Reports $46M Cash, $0.00 EPS, Advances Paxalisib, NDL2, EVT801, MSETC, No Debt, 11.4M Shares

SEC filing KZIA Appoints Dr. Sudha Rao CSO to Lead Oncology Platform, Paxalisib, NDL2, MSETC

News Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

SEC filing KZIA Reports $69.5M Cash, $12.6M Loss, Advances Paxalisib in Breast Cancer Trials

SEC filing 8-K Filing

News Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Get push alerts for KZIA

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS